DHODH and myeloid sarcoma: Similar to teriflunomide, which is already approved for MS, vidofludimus calcium inhibits the enzyme dihydroorotate dehydrogenase (DHODH) in the mitochondria and thus prevents the de novo synthesis of pyrimidine in activated lymphocytes, leading to altered cell proliferation and apoptosis [79].